Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Lymphoma, B-Cell

Trial Information

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Official Title: A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Summary

The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Phase: Phase 2

Sponsor: SymBio Pharmaceuticals

Overall Contacts:

Masahiro Furukawa
81-3-5472-1127

Toshihiko Nagase
Phone: 81-3-5472-1127

Locations (18)

Country State City Zip Facility and Contact
Japan Aichi Nagoya Research Site
Japan Ehime Matsuyama Research Site
Japan Fukuoka Kurume Research Site
Japan Gunma Maebashi Research Site
Japan Hokkaido Sapporo Research Site
Japan Ishikawa Kanazawa Research Site
Japan Kanagawa Isehara Research Site
Japan Kumamoto Ninomaru Research Site
Japan Miyagi Sendai Research Site
Japan Okayama Kurashiki Research Site
Japan Okayama Shikata-cho Research Site
Japan Saitama Hidaka Research Site
Japan Shimane Izumo Research Site
Japan Tokyo Chuo-ku Research Site
Japan Akita Research Site
Japan Fukuoka Research Site
Japan Kagoshima Research Site
Japan Kyoto Research Site

NCT ID:NCT01118845

Date Last Changed: May 27, 2010